Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Investor Update - November 14, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
If approved, Tecentriq subcutaneous (SC) would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approx. 80%1 The CHMP recommended Tecentriq SC for all indications of intravenous (IV) Tecentriq, including certain types of lung, liver, bladder and breast cancer2A majority of healthcare professionals surveyed in the IMscin001 study found that the SC formulation is easy to administer and could save time compared with IV1Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency ’s Committee for Medicinal Products for Human Use (C...
Source: Roche Media News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Lambert-Eaton Myasthenic Syndrome Underdiagnosed Alongside SCLC in the U.S.
(MedPage Today) -- PHOENIX -- While Lambert-Eaton myasthenic syndrome (LEMS) is known to be associated with small cell lung cancer (SCLC), researchers here suggested the autoimmune disorder is underdiagnosed in the U.S.
Using claims from a large... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 2, 2023 Category: Hematology Source Type: news
Bi-Specific T-Cell Engager Active in Small-Cell Lung Cancer in Third Line and Beyond
(MedPage Today) -- MADRID -- Patients with previously treated small-cell lung cancer (SCLC) obtained durable responses with either of two doses of the bispecific T cell-engaging (BiTE) antibody tarlatamab, according to a study reported here.... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 22, 2023 Category: Hematology Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Media News - October 18, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa reduces the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage non-small cell lung cancer
These Phase III data are the first and only to show an improvement in disease-free survival in early-stage resected ALK-positive non-small cell lung cancer (NSCLC)With about one in two people with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy,1 more effective treatment options are urgently needed to provide the best chance for cure2Data are being presented as a late-breaking oral during the ESMO 2023 Presidential SymposiumBasel, 18 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the primary analysis of the Phase III ALINA study demonstratin...
Source: Roche Investor Update - October 18, 2023 Category: Pharmaceuticals Source Type: news
Higher-Dose Radiotherapy Can Improve Survival in SCLC Higher-Dose Radiotherapy Can Improve Survival in SCLC
Patients with limited-stage small cell lung cancer demonstrated better overall and progression-free survival on higher-dose thoracic radiotherapy vs standard treatment, new data show.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 6, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Reducing Cognitive Impairment From SCLC Brain Metastases Reducing Cognitive Impairment From SCLC Brain Metastases
Stereotactic radiosurgery was better at preventing loss of verbal recall function at 3 months than whole-brain radiation therapy, the current standard of care for patients with brain metastases from small cell lung cancer.Medscape Medical News (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - October 4, 2023 Category: Radiology Tags: Hematology-Oncology News Source Type: news
First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLC
(MedPage Today) -- SINGAPORE -- Adding the investigational combination of PD-L1 inhibitor benmelstobart and antiangiogenic tyrosine kinase inhibitor anlotinib to first-line chemotherapy significantly improved survival in extensive-stage small... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 11, 2023 Category: Hematology Source Type: news
Roche ’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
ALINA data demonstrateAlecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cureThese data will be submitted to health authorities globallyand presented at an upcoming medical meetingBasel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecens...
Source: Roche Media News - September 1, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Alecensa delivers unprecedented Phase III results for people with ALK-positive early-stage lung cancer
ALINA data demonstrateAlecensa reduces disease recurrence in the early setting for people with ALK-positive non-small cell lung cancer (NSCLC), building on its long-established benefit in the advanced settingAbout half of people with NSCLC experience disease recurrence following surgery, despite adjuvant chemotherapy, therefore new treatments are urgently needed to provide the best chance for cureThese data will be submitted to health authorities globallyand presented at an upcoming medical meetingBasel, 01 September 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Phase III ALINA study evaluating Alecens...
Source: Roche Investor Update - September 1, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Investor Update - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Investor Update - April 16, 2023 Category: Pharmaceuticals Source Type: news
